摘要
多发性硬化(MS)是主要以中枢神经系统(CNS)白质脱髓鞘病变为主要特点的自身免疫性疾病。生物标记物是中枢神经系统自身免疫性疾病病因、诊断和预后的重要参考因素,因为他们可能反映遗传以及环境变化所引起的某些免疫反应的存在,性质和强度。因此生物标记有助于MS的早期诊断和鉴别诊断,指导治疗方案,推断MS疾病活动性,以及判断疗效。本文概述了多发性硬化领域当前的生物标记物研究状况及其相关的临床实践,并通过对三种具有较大潜力的生物标记物与病理的特异性、灵敏度、可靠性和临床实用工具进行分析,以确定最优化的治疗以防止致残,同时还可以对疾病修饰药物的有效性进行测试。
Multiple sclerosis（MS） is an autoimmune disease with the main features of central nervous system（CNS） white matter demyelination. Since they can reflect the genetic, the certain immune responses and the nature and intensity caused by environmental changes, It is an important reference for biomarkers to determine the etiology, diagnosis and prognosis of the autoimmune disease of the central nervous system. Therefore, biomarkers are used to diagnose and distinguish MS early, which can be used for guiding the options of treatment, inferring the disease activity of MS, and determining the efficacy of MS. This paper outlines the current state of research in the field of multiple sclerosis biomarkers and their associated clinical practice, analyzes the specificity, the sensitivity,the reliability and the clinical utility between the three kinds of biomarkers with great potential and pathology, determining the optimal treatment to prevent disability and testing the effectiveness of disease-modifying drugs.
出处
《现代生物医学进展》
CAS
2015年第16期3183-3185,共3页
Progress in Modern Biomedicine
基金
国家自然科学基金项目(81171120)
